Search results
Results from the WOW.Com Content Network
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [2] [4] Lecanemab is an amyloid beta-directed antibody. [2] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [2]
Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infections. [ 3 ] [ 4 ] Bezlotoxumab binds to Clostridioides difficile toxin B. [ 3 ]
The IV treatment is for patients referred by a doctor. But as more and more people seek the treatment, supply lags behind demand
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting. [ 2 ] Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in ...
The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, [11] joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections. [12] Because guselkumab is a new medicine, the long-term effects are not fully understood. [13]
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]